Unilever Exiting OTC Diagnostics Business With Unipath Sale
This article was originally published in The Tan Sheet
Executive Summary
Unilever plans to divest its nearly $90 mil. Unipath women's health diagnostics business, which includes the Clearblue line of home pregnancy test kits, to focus on selected consumer brands, the firm said June 19.
You may also be interested in...
Inverness Acquisition Of Unipath Could Lead To New Cardiology Diagnostics
Inverness Medical Innovations' acquisition of home pregnancy test manufacturer Unipath and its immunodiagnostic technologies could lead to new self-diagnostic tools in the cardiology arena
Inverness Acquisition Of Unipath Could Lead To New Cardiology Diagnostics
Inverness Medical Innovations' acquisition of home pregnancy test manufacturer Unipath and its immunodiagnostic technologies could lead to new self-diagnostic tools in the cardiology arena
Inverness Acquisition Of Unipath Could Lead To New Cardiology Diagnostics
Inverness Medical Innovations' acquisition of home pregnancy test manufacturer Unipath and its immunodiagnostic technologies could lead to new self-diagnostic tools in the cardiology arena